SCHEMBL12726150

SCHEMBL12726150

CS(=O)(=O)c1ccc(C(=O)Nc2ccc(-c3cn4ccccc4n3)cc2)c(Oc2ccncc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC6 Q9UBN7 1/20 0.53
▸ CYP1A2 P05177 1/20 0.51
▸ KDM4E B2RXH2 12/20 0.50
▸ SMN1; SMN2 Q16637 10/20 0.50
▸ ALDH1A1 P00352 7/20 0.50
▸ RAB9A P51151 7/20 0.50
▸ MAPT P10636 6/20 0.50
▸ NPC1 O15118 5/20 0.50
▸ KMT2A Q03164 4/20 0.50
▸ POLB P06746 4/20 0.50
▸ HTT P42858 2/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ HPGD P15428 6/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ PKM P14618 1/20 0.48
▸ NPSR1 Q6W5P4 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ ADRB2 P07550 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12726138 0.91 KDM4E (0.59) HDAC6CYP1A2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL12726167 0.87 KDM4E (0.58) CYP1A2KDM4ESMN1; SMN2ALDH1A1RAB9A
SCHEMBL15107970 0.87 MAPT (0.49) KDM4ESMN1; SMN2ALDH1A1RAB9AMAPT
SCHEMBL12726115 0.83 HDAC6 (0.62) HDAC6CYP1A2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL12726113 0.83 CYP1A2 (0.63) HDAC6CYP1A2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL15107975 0.78 KDM4E (0.50) KDM4ESMN1; SMN2ALDH1A1RAB9AMAPT
SCHEMBL12726127 0.77 HDAC6 (0.53) HDAC6CYP1A2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL12726122 0.76 HDAC6 (0.52) HDAC6CYP1A2KDM4ESMN1; SMN2ALDH1A1
SCHEMBL15107973 0.76 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1RAB9AMAPT
SCHEMBL12726045 0.76 ALDH1A1 (0.52) KDM4ESMN1; SMN2ALDH1A1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486936-B2 Antagonist of smoothened AllaChem, LLC (US) 2013-07-16 — — US disclosed
US-8486936-B2 Antagonist of smoothened AllaChem, LLC (US) 2013-07-16 — — US disclosed
US-20110098291-A1 ANTAGONIST OF SMOOTHENED Alla Chem Inc. (US) 2011-04-28 — — US disclosed
US-20110098291-A1 ANTAGONIST OF SMOOTHENED Alla Chem Inc. (US) 2011-04-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098291-A1 ANTAGONIST OF SMOOTHENED SMO, SHH, GLI1 HDAC6 450/4885CYP1A2 4552/4885KDM4E 1596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback